## Angelo Andriulli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1850867/publications.pdf

Version: 2024-02-01

351 papers 17,541 citations

70 h-index 117 g-index

361 all docs

361 docs citations

361 times ranked

17333 citing authors

#	Article	IF	CITATIONS
1	Incidence Rates of Post-ERCP Complications: A Systematic Survey of Prospective Studies. American Journal of Gastroenterology, 2007, 102, 1781-1788.	0.2	947
2	Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine, 2005, 352, 2609-2617.	13.9	672
3	Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics, 2010, 42, 332-337.	9.4	572
4	Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Updated June 2014. Endoscopy, 2014, 46, 799-815.	1.0	521
5	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
6	European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis. Endoscopy, 2010, 42, 503-515.	1.0	274
7	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. New England Journal of Medicine, 2012, 367, 716-724.	13.9	274
8	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2009, 104, 514-524.	0.2	239
9	Randomized Controlled Trial of Botulinum Toxin Versus Laparoscopic Heller Myotomy for Esophageal Achalasia. Annals of Surgery, 2004, 239, 364-370.	2.1	229
10	Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology, 2008, 47, 43-50.	3.6	225
11	Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology, 2006, 44, 713-720.	3.6	222
12	A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut, 2000, 46, 597-600.	6.1	204
13	Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointestinal Endoscopy, 2000, 51, 1-7.	0.5	199
14	Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome, 2018, 6, 92.	4.9	192
15	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. Journal of Hepatology, 2007, 46, 206-212.	1.8	188
16	Aberrant DNA Methylation in Non-Neoplastic Gastric Mucosa of H. Pylori Infected Patients and Effect of Eradication. American Journal of Gastroenterology, 2007, 102, 1361-1371.	0.2	173
17	Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. Annals of Surgical Oncology, 2012, 19, 1644-1662.	0.7	170
18	Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. Gastroenterology, 2007, 133, 465-471.	0.6	161

#	Article	IF	Citations
19	Randomized study of two "rescue" therapies for helicobacter pylori-infected patients after failure of standard triple therapies. American Journal of Gastroenterology, 2001, 96, 58-62.	0.2	155
20	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	0.5	151
21	Characteristics of hepatocellular carcinoma in Italy. Journal of Hepatology, 1998, 29, 944-952.	1.8	146
22	Italian consensus guidelines for chronic pancreatitis. Digestive and Liver Disease, 2010, 42, S381-S406.	0.4	140
23	Mirna Expression Profiles Identify Drivers in Colorectal and Pancreatic Cancers. PLoS ONE, 2012, 7, e33663.	1.1	138
24	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	0.5	134
25	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointestinal Endoscopy, 2007, 65, 624-632.	0.5	130
26	Rifabutin-based â€rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Alimentary Pharmacology and Therapeutics, 2000, 14, 311-316.	1.9	128
27	Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. World Journal of Gastroenterology, 2006, 12, 3636.	1.4	125
28	Smoking as a Cofactor for Causation of Chronic Pancreatitis. Pancreas, 2010, 39, 1205-1210.	0.5	124
29	Clock Gene Expression Levels and Relationship With Clinical and Pathological Features in Colorectal Cancer Patients. Chronobiology International, 2011, 28, 841-851.	0.9	123
30	Outcome of chronic delta hepatitis in Italy: A long-term cohort study. Journal of Hepatology, 2010, 53, 834-840.	1.8	122
31	Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut, 2004, 53, 1356-1362.	6.1	121
32	Gastrointestinal Motility Disorders in Patients with Inactive Crohn's Disease. Scandinavian Journal of Gastroenterology, 1997, 32, 1107-1117.	0.6	120
33	Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology, 1999, 117, 161-166.	0.6	120
34	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48, 1906-1912.	3.6	120
35	HCV and diabetes mellitus: evidence for a negative association. American Journal of Gastroenterology, 1998, 93, 2363-2367.	0.2	118
36	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.2	116

#	Article	IF	CITATIONS
37	The PROSIT-BIO Cohort. Inflammatory Bowel Diseases, 2017, 23, 233-243.	0.9	116
38	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	0.6	116
39	Helicobacter pylori infection and growth delay in older children. Archives of Disease in Childhood, 1997, 77, 46-49.	1.0	115
40	Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. American Journal of Gastroenterology, 1998, 93, 2082-2088.	0.2	115
41	HLA class II favors clearance of HCV infection and progression of the chronic liver damage. Journal of Hepatology, 1999, 30, 984-989.	1.8	113
42	Cancer risk associated with STK11/LKB1 germline mutations in Peutz–Jeghers syndrome patients: Results of an Italian multicenter study. Digestive and Liver Disease, 2013, 45, 606-611.	0.4	113
43	The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology, 1997, 25, 728-734.	3.6	110
44	Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Alimentary Pharmacology and Therapeutics, 2005, 22, 227-232.	1.9	108
45	Clinical Features of Reflux Esophagitis in Older People: A Study of 840 Consecutive Patients. Journal of the American Geriatrics Society, 2006, 54, 1537-1542.	1.3	107
46	Gastrointestinal Motor Dysfunction, Symptoms, and Neuropathy in Noninsulin-Dependent (Type 2) Diabetes Mellitus. Journal of Clinical Gastroenterology, 1999, 29, 171-177.	1.1	106
47	Metaâ€analysis: the outcome of antiâ€viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 397-404.	1.9	104
48	ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 501-511.	1.2	104
49	Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas. World Journal of Gastroenterology, 2013, 19, 7930.	1.4	98
50	Predictors of failure of Helicobacter pylori eradication with the standard †Maastricht triple therapyâ€. Alimentary Pharmacology and Therapeutics, 2001, 15, 1023-1029.	1.9	97
51	Prophylaxis of ERCP-related pancreatitis: A randomized, controlled trial of somatostatin and gabexate mesylate 1 1The trial was designed and the manuscript was written by Dr. Andriulli. No pharmaceutical or private grants were searched for or made available for performing the present work Clinical Gastroenterology and Hepatology, 2004, 2, 713-718.	2.4	97
52	Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Alimentary Pharmacology and Therapeutics, 1998, 12, 237-245.	1.9	96
53	Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Journal of Hepatology, 2002, 36, 799-804.	1.8	96
54	Proton-Pump Inhibitors and Outcome of Endoscopic Hemostasis in Bleeding Peptic Ulcers: A Series of Metaanalyses. American Journal of Gastroenterology, 2005, 100, 207-219.	0.2	95

#	Article	IF	CITATIONS
55	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. American Journal of Gastroenterology, 2007, 102, 601-608.	0.2	95
56	Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointestinal Endoscopy, 2010, 71, 927-933.	0.5	93
57	Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. European Journal of Internal Medicine, 2017, 38, 79-82.	1.0	92
58	IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine, 2004, 25, 103-109.	1.4	90
59	The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylorigastritis. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 19-28.	0.6	88
60	Pancreatic Duct Stents in the Prophylaxis of Pancreatic Damage after Endoscopic Retrograde Cholangiopancreatography: A Systematic Analysis of Benefits and Associated Risks. Digestion, 2007, 75, 156-163.	1.2	84
61	Polymorphism of the IRGM Gene Might Predispose to Fistulizing Behavior in Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 110-116.	0.2	82
62	Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus $\hat{a}\in$ A GISC study. European Journal of Human Genetics, 1999, 7, 567-573.	1.4	81
63	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. European Journal of Gastroenterology and Hepatology, 2005, 17, 745-751.	0.8	81
64	High- <i>Versus</i> Low-Dose Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding: A Multicentre, Randomized Study. American Journal of Gastroenterology, 2008, 103, 3011-3018.	0.2	80
65	Anticardiolipin Antibodies in Patients With Liver Disease. American Journal of Gastroenterology, 1999, 94, 2983-2987.	0.2	78
66	13C-octanoic acid breath test for gastric emptying measurement. European Journal of Gastroenterology and Hepatology, 2000, 12, 85-91.	0.8	78
67	Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemotherapy and Pharmacology, 2018, 81, 773-782.	1.1	76
68	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e62144.	1.1	75
69	A modified fast-track program for pancreatic surgery: a prospective single-center experience. Langenbeck's Archives of Surgery, 2011, 396, 345-351.	0.8	73
70	Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. American Journal of Gastroenterology, 2002, 97, 397-405.	0.2	72
71	Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. American Journal of Gastroenterology, 2001, 96, 2407-2412.	0.2	71
72	Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study. American Journal of Gastroenterology, 2005, 100, 1370-1375.	0.2	71

#	Article	IF	Citations
73	Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics, 2004, 20, 1091-1097.	1.9	70
74	Hemangioma-like Lesions in Chronic Liver Disease: Diagnostic Evaluation in Patients. Radiology, 2001, 220, 337-342.	3 <b>.</b> 6	69
75	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. European Journal of Internal Medicine, 2018, 53, 79-84.	1.0	69
76	Loss of Connectivity in Cancer Co-Expression Networks. PLoS ONE, 2014, 9, e87075.	1.1	68
77	Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget, 2016, 7, 5815-5829.	0.8	68
78	Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis. Clinical Genetics, 2001, 59, 189-193.	1.0	67
79	Intrafamilial transmission of hepatitis delta virus: molecular evidence. Journal of Hepatology, 1999, 30, 564-569.	1.8	66
80	Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. American Journal of Gastroenterology, 2008, 103, 2509-2516.	0.2	66
81	Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S218-S223.	1.1	65
82	Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia., 1998, 21, 1540-1542.		64
83	Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology, 2009, 49, 358-363.	3.6	64
84	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
85	Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 22, 1129-1138.	1.9	60
86	Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine, 2005, 30, 293-302.	1.4	58
87	Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-Â in Huh-7 cells. Journal of General Virology, 2010, 91, 1678-1686.	1.3	58
88	Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 497-506.	1.9	57
89	Randomised clinical trial: lowâ€volume bowel preparation for colonoscopy ―a comparison between two different <scp>PEG</scp> â€based formulations. Alimentary Pharmacology and Therapeutics, 2012, 36, 717-724.	1.9	57
90	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57

#	Article	IF	Citations
91	The impact of infection by multidrugâ€resistant agents in patients with cirrhosis. A multicenter prospective study. Liver International, 2017, 37, 71-79.	1.9	57
92	Helicobacter pylori Infection May Undergo Spontaneous Eradication in Children: A 2-Year Follow-Up Study. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 181-183.	0.9	57
93	Randomized study of different â€~second-line' therapies for Helicobacter pylori infection after failure of the standard â€~Maastricht triple therapy'. Alimentary Pharmacology and Therapeutics, 2003, 18, 815-820.	1.9	56
94	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Digestive and Liver Disease, 2010, 42, 81-91.	0.4	56
95	Circulating trypsin-like immunoreactivity in chronic pancreatitis. Digestive Diseases and Sciences, 1981, 26, 532-537.	1.1	55
96	Treatment of Antibiotic-ResistantHelicobacter pyloriInfection. New England Journal of Medicine, 1998, 339, 53-53.	13.9	55
97	The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal antiinflammatory drugs: The role of gastroprotective drugs. Aging Clinical and Experimental Research, 2003, 15, 494-499.	1.4	55
98	Fatal Systemic Venous Air Embolism During Endoscopic Retrograde Cholangiopancreatography. Advances in Anatomic Pathology, 2009, 16, 255-262.	2.4	55
99	DNA Methyltransferases 1 and 3b Expression in Huh-7 Cells Expressing HCV Core Protein of Different Genotypes. Digestive Diseases and Sciences, 2012, 57, 1598-1603.	1.1	55
100	Perendoscopic injection of botulinum toxin is effective in achalasia after failure of myotomy or pneumatic dilation. Gastrointestinal Endoscopy, 1996, 44, 461-465.	0.5	54
101	Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncology, 2013, 9, 283-294.	1.1	54
102	Investigation of Multiple Susceptibility Loci for Inflammatory Bowel Disease in an Italian Cohort of Patients. PLoS ONE, 2011, 6, e22688.	1.1	53
103	Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. Alimentary Pharmacology and Therapeutics, 1999, 13, 1347-1350.	1.9	52
104	Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Alimentary Pharmacology and Therapeutics, 2001, 15, 965-972.	1.9	52
105	SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation. Aging, 2014, 6, 35-47.	1.4	51
106	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	0.9	51
107	Mutation analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the cationic trypsinogen (PRSS1) gene, and the serine protease inhibitor, Kazal type 1 (SPINK1) gene in patients with alcoholic chronic pancreatitis. European Journal of Human Genetics, 2003, 11, 687-692.	1.4	50
108	Fineâ€needle liver biopsy in patients with severely impaired coagulation. Liver, 1993, 13, 270-273.	0.1	50

7

#	Article	IF	CITATIONS
109	Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. Chronobiology International, 2015, 32, 903-916.	0.9	50
110	A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology, 2001, 33, 989-993.	3.6	48
111	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2006, 12, 7821.	1.4	48
112	Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver International, 2005, 25, 1175-1181.	1.9	47
113	Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Alimentary Pharmacology and Therapeutics, 2005, 22, 769-774.	1.9	46
114	A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. Journal of Viral Hepatitis, 2005, 12, 292-299.	1.0	45
115	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 2013, 45, 95-99.	0.4	45
116	Detection of abnormal lesions recorded by capsule endoscopyA prospective study comparing endoscopist's and nurse's accuracy. Digestive and Liver Disease, 2006, 38, 599-602.	0.4	44
117	HCV genotypes in patients with liver disease of different stages and severity. Journal of Hepatology, 1997, 26, 1173-1178.	1.8	43
118	An optimized experimental protocol based on neuro-evolutionary algorithms. Artificial Intelligence in Medicine, 2005, 34, 279-305.	3.8	43
119	Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes. PLoS ONE, 2013, 8, e60527.	1.1	43
120	HBsAg kinetics in chronic hepatitis D during interferon therapy: onâ€treatment prediction of response. Alimentary Pharmacology and Therapeutics, 2016, 44, 620-628.	1.9	43
121	Gastric Emptying of Solids in Patients with Nonobstructive Crohn $\hat{E}^{1}\!\!/4$ s Disease Is Sometimes Delayed. Journal of Clinical Gastroenterology, 1995, 21, 279-282.	1.1	42
122	Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon $\hat{l}_{\pm}$ -2b for chronic hepatitis type C. Journal of Hepatology, 1997, 27, 56-62.	1.8	42
123	Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal Cancers. Digestion, 1986, 33, 26-33.	1.2	41
124	Coarse Nodular US Pattern in Hepatic Cirrhosis: Risk for Hepatocellular Carcinoma. Radiology, 2003, 226, 691-697.	3.6	41
125	Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Alimentary Pharmacology and Therapeutics, 2007, 26, 737-745.	1.9	41
126	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	0.8	41

#	Article	IF	CITATIONS
127	Changes in miR-143 and miR-21 Expression and Clinicopathological Correlations in Pancreatic Cancers. Pancreas, 2012, 41, 1280-1284.	0.5	39
128	Lack of association between <i>UGT1A7, UGT1A9, ARP, SPINK1</i> and <i>CFTR</i> gene polymorphisms and pancreatic cancer in Italian patients. World Journal of Gastroenterology, 2006, 12, 6343.	1.4	39
129	The A16V signal peptide cleavage site mutation in the cationic trypsinogen gene and chronic pancreatitis. Gastroenterology, 1999, 117, 1508-1509.	0.6	38
130	Combination therapy with amantadine and interferon in naıÌ`ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. Journal of Hepatology, 2004, 40, 478-483.	1.8	38
131	Association Study of a Polymorphism in Clock GenePERIOD3and Risk of Inflammatory Bowel Disease. Chronobiology International, 2012, 29, 994-1003.	0.9	38
132	Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Alimentary Pharmacology and Therapeutics, 1997, 11, 599-603.	1.9	37
133	Interplay between SOX9, $\hat{I}^2$ -catenin and PPAR $\hat{I}^3$ activation in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1853-1865.	1.9	36
134	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	2.3	36
135	Hypoechoic lesions in the †bright liver': A reliable indicator of fatty change. A prospective study. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 469-472.	1.4	35
136	Fatal ulcerative panenteritis following colectomy in a patient with ulcerative colitis. Digestive Diseases and Sciences, 1999, 44, 1189-1195.	1.1	35
137	Usefulness of the Comprehensive Geriatric Assessment in Older Patients with Upper Gastrointestinal Bleeding: A Two-Year Follow-Up Study. Digestive Diseases, 2007, 25, 124-128.	0.8	35
138	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: A meta-analysis. Inflammatory Bowel Diseases, 2007, 13, 1212-1219.	0.9	35
139	External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. American Journal of Gastroenterology, 2005, 100, 868-873.	0.2	34
140	HLA and enteric antineuronal antibodies in patients with achalasia. Neurogastroenterology and Motility, 2006, 18, 520-525.	1.6	34
141	Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2011, 9, 249-253.	2.4	34
142	Forecasting Hepatitis C liver disease burden on realâ€life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	1.9	33
143	Free-hand technique with ordinary antisepsis in abdominal US-guided fine-needle punctures: three-year experience Radiology, 1996, 199, 721-723.	3.6	32
144	Promoter methylation correlates with reduced NDRG2expression in advanced colon tumour. BMC Medical Genomics, 2009, 2, 11.	0.7	32

#	Article	IF	Citations
145	Tailoring the length of antiviral treatment for hepatitis C. Gut, 2010, 59, 1-5.	6.1	32
146	Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies. Liver, 2001, 21, 254-259.	0.1	31
147	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. Digestive and Liver Disease, 2004, 36, 121-124.	0.4	31
148	Experts' opinions on the role of liver biopsy in HCV infection: A Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). Journal of Hepatology, 2005, 43, 381-387.	1.8	31
149	The association of <i>MYO9B</i> gene in Italian patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2008, 27, 241-248.	1.9	31
150	HCV chronic infection and CCR5-Δ32ſĨ"32. Gastroenterology, 2003, 124, 868-869.	0.6	30
151	CARD15 Genotyping in Inflammatory Bowel Disease Patients by Multiplex Pyrosequencing. Clinical Chemistry, 2003, 49, 1675-1679.	1.5	30
152	HLA-DRB1 Alleles May Influence Disease Phenotype in Patients With Inflammatory Bowel Disease: A Critical Reappraisal With Review of the Literature. Diseases of the Colon and Rectum, 2005, 48, 57-65.	0.7	30
153	Short-term treatment duration for HCV-2 and HCV-3 infected patients. Digestive and Liver Disease, 2006, 38, 741-748.	0.4	29
154	Diagnostic accuracy of serum cationic trypsinogen estimation for pancreatic diseases. Digestive Diseases and Sciences, 1982, 27, 1089-1094.	1.1	28
155	Gross Pathologic Types of Hepatocellular Carcinoma in Italy. Oncology, 1999, 56, 189-192.	0.9	28
156	Amoxicillin-Tetracycline Combinations are Inadequate as Alternative Therapies for Helicobacter pylori Infection. Helicobacter, 2002, 7, 99-104.	1.6	28
157	Sustained virological responses following standard antiâ€viral therapy in decompensated HCVâ€infected cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2009, 30, 146-153.	1.9	28
158	Exploring the microbiota to better understand gastrointestinal cancers physiology. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1400-1412.	1.4	28
159	Efficacy of 5 MU of interferon in combination with ribavirin for naıÌ've patients with chronic hepatitis C virus: a randomized controlled trial. Journal of Hepatology, 2001, 34, 441-446.	1.8	27
160	Contribution of IBD5 Locus to Clinical Features of IBD Patients. American Journal of Gastroenterology, 2006, 101, 318-325.	0.2	27
161	Hepatitis delta virus induces specific DNA methylation processes in Huhâ€7 liver cancer cells. FEBS Letters, 2013, 587, 1424-1428.	1.3	27
162	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	0.6	27

#	Article	IF	CITATIONS
163	Intraduodenal Lipase Activity in Celiac Disease Assessed by Means of 13C Mixed-Triglyceride Breath Test. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 407-410.	0.9	27
164	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002, 51, 864-869.	6.1	26
165	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology, 2010, 53, 1000-1005.	1.8	26
166	Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World Journal of Gastroenterology, 2008, 14, 6467.	1.4	26
167	13C octanoic acid breath test. Gut, 1998, 43, S28-S28.	6.1	25
168	Antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Diseases of the Colon and Rectum, 2000, 43, 999-1007.	0.7	25
169	Identification of $na\tilde{A}$ ve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. Journal of Hepatology, 2014, 60, 16-21.	1.8	25
170	Peroxisome proliferator-activated receptor $\hat{l}^3$ -mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1225-1236.	1.9	25
171	Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 44.	1.3	25
172	Hepatic Hydrothorax. Clinical Nuclear Medicine, 1996, 21, 56-60.	0.7	25
173	Candida Overgrowth in Gastric Juice of Peptic Ulcer Subjects on Short- and Long-Term Treatment with H <sub>2</sub> -Receptor Antagonists. Digestion, 1983, 28, 158-163.	1.2	24
174	Contribution of artificial neural networks to the classification and treatment of patients with uninvestigated dyspepsia. Digestive and Liver Disease, 2003, 35, 222-231.	0.4	24
175	The â°'A2518G Polymorphism of Monocyte Chemoattractant Protein-1 Is Associated With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 1586-1594.	0.2	24
176	Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients., 1999, 59, 277-280.		23
177	Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Digestive Diseases and Sciences, 2001, 46, 1409-1415.	1.1	23
178	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's and Colitis, 2012, 6, 563-570.	0.6	23
179	Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Scientific Reports, 2016, 6, 31549.	1.6	23
180	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. European Journal of Internal Medicine, 2017, 38, 68-72.	1.0	23

#	Article	IF	CITATIONS
181	Genomeâ€wide scan of long noncoding <scp>RNA</scp> single nucleotide polymorphism <scp>s</scp> and pancreatic cancer susceptibility. International Journal of Cancer, 2021, 148, 2779-2788.	2.3	23
182	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. Journal of Hepatology, 2009, 51, 675-681.	1.8	22
183	Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1108-1117.	0.9	22
184	Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	22
185	Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	22
186	Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Digestive Diseases and Sciences, 1996, 41, 1065-1068.	1.1	21
187	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Journal of Hepatology, 2002, 37, 109-116.	1.8	21
188	Influence of preoperative biliary drainage on surgical outcome after pancreaticoduodenectomy: single centre experience. Langenbeck's Archives of Surgery, 2014, 399, 649-57.	0.8	21
189	Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?. World Journal of Gastroenterology, 2009, 15, 2456.	1.4	21
190	13C-octanoic acid breath test: Valueless test for gastric emptying?. Gastroenterology, 1998, 114, 857-858.	0.6	20
191	Ranitidine bismuth citrate-based triple therapies after failure of the standard †Maastricht triple therapy': a promising alternative to the quadruple therapy?. Alimentary Pharmacology and Therapeutics, 2001, 15, 1017-1022.	1.9	20
192	Genetics of inflammatory bowel disease. Digestive and Liver Disease, 2003, 35, 442-449.	0.4	20
193	SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. Chronobiology International, 2015, 32, 497-512.	0.9	20
194	Genomeâ€wide association study identifies an early onset pancreatic cancer risk locus. International Journal of Cancer, 2020, 147, 2065-2074.	2.3	20
195	Hydrothorax Complicating Cirrhosis in the Absence of Ascites. Journal of Clinical Gastroenterology, 1993, 17, 271-272.	1.1	19
196	Linkage analysis identifies gene carriers among members of families with hereditary nonpolyposis colorectal cancer. Gastroenterology, 1996, 110, 1404-1409.	0.6	19
197	Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Digestive and Liver Disease, 2000, 32, 378-383.	0.4	19
198	Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Alimentary Pharmacology and Therapeutics, 2004, 20, 1143-1152.	1.9	19

#	Article	IF	CITATIONS
199	Treatment of patients with HCV infection with or without liver biopsy. Journal of Viral Hepatitis, 2004, 11, 536-542.	1.0	19
200	Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the locus. Digestive and Liver Disease, 2005, 37, 312-315.	0.4	19
201	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	1.4	19
202	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. Digestive and Liver Disease, 2017, 49, 1022-1028.	0.4	19
203	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
204	Combined segregation and linkage analysis of inflammatory bowel disease in the IBD1 region using severity to characterise Crohn's disease and ulcerative colitis. European Journal of Human Genetics, 2000, 8, 846-852.	1.4	18
205	The expression of leucine-rich repeat gene family members in colorectal cancer. Experimental Biology and Medicine, 2012, 237, 1123-1128.	1.1	18
206	Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Digestive and Liver Disease, 2021, 53, 277-282.	0.4	18
207	Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. International Journal of Molecular Sciences, 2017, 18, 1580.	1.8	17
208	Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Oncotarget, 2016, 7, 8968-8978.	0.8	17
209	Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation. Liver Transplantation, 2004, 10, 1355-1363.	1.3	16
210	SIRT1 and the Clock Gene Machinery in Colorectal Cancer. Cancer Investigation, 2012, 30, 98-105.	0.6	16
211	Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon. BMC Cancer, 2012, 12, 608.	1.1	16
212	Longâ€term outcome of hepatitis <scp>B</scp> virusâ€related <scp>C</scp> hronic <scp>H</scp> epatitis under protracted nucleos(t)ide analogues. Journal of Viral Hepatitis, 2013, 20, 502-509.	1.0	16
213	Inflammatory Bowel Disease Meets Systems Biology: A Multi-Omics Challenge and Frontier. OMICS A Journal of Integrative Biology, 2016, 20, 692-698.	1.0	16
214	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis, 2018, 39, 360-367.	1.3	16
215	Hepatitis C virus, mitochondria and auto/mitophagy: Exploiting a host defense mechanism. World Journal of Gastroenterology, 2014, 20, 2624.	1.4	16
216	Monthly fluctuations of active duodenal ulcers. Digestive Diseases and Sciences, 1984, 29, 983-987.	1.1	15

#	Article	IF	CITATIONS
217	Dyspepsia and Helicobacter pylori infection: a prospective multicentre observational study. Digestive and Liver Disease, 2003, 35, 157-164.	0.4	15
218	Comparison of a monoclonal antigen stool test (Hp StAR) with the 13C-urea breath test (UBT) in monitoring <i>Helicobacter pylori</i> eradication therapy. World Journal of Gastroenterology, 2005, 11, 5878.	1.4	15
219	"Appropriateness―or "prioritization―for GI endoscopic procedures?. Gastrointestinal Endoscopy, 2006, 63, 1034-1036.	0.5	15
220	Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with pegâ€interferon αâ€2b and ribavirin. Alimentary Pharmacology and Therapeutics, 2010, 31, 1346-1353.	1.9	15
221	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	1.8	15
222	Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. Digestive and Liver Disease, 2002, 34, 285-289.	0.4	14
223	Correlations among PPAR, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. PPAR Research, 2012, 2012, 1-7.	1.1	14
224	Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. International Journal of Cancer, 2018, 142, 290-296.	2.3	14
225	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 1037-1045.	1.3	14
226	Cruveilhier-Baumgarten syndrome: An efficient spontaneous portosystemic collateral preventing oesophageal varices bleeding. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 236-241.	1.4	13
227	Absence of Benefit of EradicatingHelicobacter pyloriin Patients with Nonulcer Dyspepsia. New England Journal of Medicine, 2000, 342, 589-590.	13.9	13
228	Transperineal ultrasonography: First level exam in IBD patients with perianal disease. Digestive and Liver Disease, 2016, 48, 874-879.	0.4	13
229	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a crossâ€sectional multicenter study. Journal of Medical Virology, 2017, 89, 2138-2143.	2.5	13
230	The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease, 2019, 51, 434-437.	0.4	13
231	Crohn's Disease Localization Displays Different Predisposing Genetic Variants. PLoS ONE, 2017, 12, e0168821.	1.1	13
232	Canrenone and Androgen Receptor-Active Materials in Plasma of Cirrhotic Patients during Long-Term K-Canrenoate or Spironolactone Therapy. Digestion, 1989, 44, 155-162.	1.2	12
233	Minute and small early gastric cancers in a Western population: a clinicopathologic study. Gastrointestinal Endoscopy, 1995, 41, 475-480.	0.5	12
234	Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines. Alimentary Pharmacology and Therapeutics, 2002, 16, 1443-1447.	1.9	12

#	Article	IF	CITATIONS
235	TNFâ€Î± Polymorphisms in Primary Biliary Cirrhosis: A Northern and Southern Italian Experience. Annals of the New York Academy of Sciences, 2009, 1173, 557-563.	1.8	12
236	Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diabetes of Recent Diagnosis. Frontiers in Oncology, 2020, 10, 1567.	1.3	12
237	Lamivudine retreatment of pts who have relapsed after a previous course of lamivudine with or without interferon. Journal of Hepatology, 2002, 36, 121-122.	1.8	11
238	Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy, 2009, 10, 1929-1938.	0.9	11
239	Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation. Familial Cancer, 2011, 10, 285-295.	0.9	11
240	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 2020, 65, 1767-1776.	1.1	11
241	microRNAâ€mRNA network model in patients with achalasia. Neurogastroenterology and Motility, 2020, 32, e13764.	1.6	11
242	Exploitation of host clock gene machinery by hepatitis viruses B and C. World Journal of Gastroenterology, 2013, 19, 8902.	1.4	11
243	Pulmonary involvement in chronic pancreatitis. Digestive Diseases and Sciences, 1984, 29, 896-901.	1.1	10
244	Subgroups of patients with Crohn's disease have different clinical outcomes. Inflammatory Bowel Diseases, 1996, 2, 1-5.	0.9	10
245	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Alimentary Pharmacology and Therapeutics, 2004, 19, 331-337.	1.9	10
246	Fundoplication After Heller Myotomy: A Retrospective Comparison Between Nissen and Dor. Eurasian Journal of Medicine, 2011, 42, 133-140.	0.2	10
247	Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. Journal of Translational Medicine, 2014, 12, 248.	1.8	10
248	Retroperitoneal neurilemoma diagnosed by endosonographically guided fine needle aspiration. Journal of Clinical Ultrasound, 2006, 34, 241-243.	0.4	9
249	Epidemiology and diagnosis of hepatitis D virus. Future Virology, 2012, 7, 709-717.	0.9	9
250	A unifying working hypothesis for juvenile polyposis syndrome and Ménétrier's disease: Specific localization or concomitant occurrence of a separate entity?. Digestive and Liver Disease, 2012, 44, 952-956.	0.4	9
251	Variation in genes encoding for interferon λâ€3 and λâ€4 in the prediction of <scp>HCV</scp> â€1 treatmentâ€induced viral clearance. Liver International, 2014, 34, 1369-1377.	1.9	9
252	Overall acceptability and efficacy of commonly used bowel preparations for colonoscopy in Italian clinical practice. A multicentre prospective study. Digestive and Liver Disease, 2014, 46, 795-802.	0.4	9

#	Article	IF	CITATIONS
253	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatology International, 2015, 9, 52-57.	1.9	9
254	Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology and Hepatology, 2020, 32, 1579-1582.	0.8	9
255	MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater's papilla adenocarcinoma. Oncotarget, 2017, 8, 105320-105339.	0.8	9
256	Does a Single Granuloma Warrant a Diagnosis of Idiopathic Granulomatous Gastritis?. Journal of Clinical Gastroenterology, 1993, 16, 261-262.	1.1	8
257	Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. Human Immunology, 2014, 75, 364-369.	1.2	8
258	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in $na\tilde{A}$ ve patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 818-825.	0.4	8
259	Hepatitis viruses exploitation of host DNA methyltransferases functions. Clinical and Experimental Medicine, 2016, 16, 265-272.	1.9	8
260	Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy. European Journal of Gastroenterology and Hepatology, 2018, 30, 676-681.	0.8	8
261	Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2021, 32, 201-207.	0.8	8
262	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Frontiers in Oncology, 2021, 11, 771312.	1.3	8
263	Polymorphism of motilin gene in patients with Crohn's disease. Digestive Diseases and Sciences, 1998, 43, 715-719.	1.1	7
264	Pancreatic Exocrine Function Tests. Scandinavian Journal of Gastroenterology, 1998, 33, 1118-1119.	0.6	7
265	Association of Crohn's disease and ulcerative colitis with haplotypes of the MLH1 gene in Italian inflammatory bowel disease patients. Journal of Medical Genetics, 2002, 39, 332-334.	1.5	7
266	First, do not harm: power, oppression, and violence of liver biopsy. Gastroenterology, 2003, 125, 272-273.	0.6	7
267	Dissecting genetic predisposition to inflammatory bowel disease: current progress and prospective application. Expert Review of Clinical Immunology, 2007, 3, 287-298.	1.3	7
268	Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: A pilot study. Digestive and Liver Disease, 2007, 39, 857-863.	0.4	7
269	Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1449-1460.	0.9	7
270	IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Inflammatory Bowel Diseases, 2011, 17, 1832-1833.	0.9	7

#	Article	IF	Citations
271	Time-Qualified Patterns of Variation of PPAR $\langle i \rangle \hat{1}^3 \langle   i \rangle$ , DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines. PPAR Research, 2012, 2012, 1-8.	1.1	7
272	Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. Digestive Diseases and Sciences, 2013, 58, 1371-1382.	1.1	7
273	Cancer sniffer dogs: how can we translate this peculiarity in laboratory medicine? Results of a pilot study on gastrointestinal cancers. Clinical Chemistry and Laboratory Medicine, 2017, 56, 138-146.	1.4	7
274	Focal Ultrasound Lesions in Cirrhotic Liver Diagnosed As Regenerative Nodules by Biopsy. Journal of Clinical Gastroenterology, 1993, 17, 67-72.	1.1	6
275	Subgroups of Patients with Crohn's Disease Have Different Clinical Outcomes. Inflammatory Bowel Diseases, 1996, 2, 1-5.	0.9	6
276	Artificial neural networks can classify uninvestigated patients with dyspepsia. European Journal of Gastroenterology and Hepatology, 2007, 19, 1055-1058.	0.8	6
277	Early discontinuation of ribavirin in HCVâ€2 and HCVâ€3 patients responding to Pegâ€interferon alphaâ€2a and ribavirin. Journal of Viral Hepatitis, 2009, 16, 28-35.	1.0	6
278	The intelligent, painless, "germ-free―colonoscopy: A Columbus' egg for increasing population adherence to colorectal cancer screening?. Digestive and Liver Disease, 2010, 42, 839-843.	0.4	6
279	Unawareness of HBV infection among inpatients in a Southern Italian hospital. Journal of Viral Hepatitis, 2011, 18, e206-11.	1.0	6
280	Hepatitis C Virus Clearance in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 85-91.	1.3	6
281	Germline Alterations in Patients With IBD-associated Colorectal Cancer. Inflammatory Bowel Diseases, 2022, 28, 447-454.	0.9	6
282	Randomized study of two "rescue―therapies for helicobacter pylori-infected patients after failure of standard triple therapies. American Journal of Gastroenterology, 2001, 96, 58-62.	0.2	5
283	On the role of CFTR, PSSR1 and PST1/SPINK1 in idiopathic chronic pancreatitis. European Journal of Human Genetics, 2003, 11, 107-108.	1.4	5
284	Linkage of ulcerative colitis to the pericentromeric region of chromosome 16 in Italian inflammatory bowel disease families is independent of the presence of common CARD15 mutations. Journal of Medical Genetics, 2003, 40, 837-841.	1.5	5
285	Risk of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Ways to Prevent It: Old Myths, a Current Need? The Case of Allopurinol. Clinical Gastroenterology and Hepatology, 2008, 6, 374-376.	2.4	5
286	Advance in molecular diagnostic tools for hepatitis B virus detection. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1707-17.	1.4	5
287	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. Alimentary Pharmacology and Therapeutics, 2016, 43, 174-175.	1.9	5
288	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. Digestive and Liver Disease, 2021, 53, 202-209.	0.4	5

#	Article	IF	CITATIONS
289	Interobserver agreement of the Paris and simplified classifications of superficial colonic lesions: a Western study. Endoscopy International Open, 2021, 09, E388-E394.	0.9	5
290	Cerebellar Metastasis as a Unique Presenting Feature of Gastric Cancer. Journal of Clinical Gastroenterology, 2001, 33, 80-81.	1.1	5
291	Etiological factors of chronic hepatitis in Italy. European Journal of Gastroenterology and Hepatology, 2017, 29, 994-997.	0.8	5
292	Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. PLoS ONE, 2017, 12, e0185710.	1.1	5
293	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.	0.8	5
294	Aminopyrine breath test. Digestive Diseases and Sciences, 1994, 39, 2445-2446.	1.1	4
295	Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. American Journal of Gastroenterology, 2001, 96, 2939-2945.	0.2	4
296	Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine. Alimentary Pharmacology and Therapeutics, 2003, 18, 933-940.	1.9	4
297	Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. Annals of Internal Medicine, 2004, 141, 78.	2.0	4
298	Bolus Versus Continuous High-Dose Omeprazole Infusion Combined with Endoscopic Hemostasis in Peptic Ulcer Bleeding. A Randomized, Multicenter, Italian Study. Gastrointestinal Endoscopy, 2007, 65, AB120.	0.5	4
299	1170 IL28B C/C POLYMORPHISM IS PREDICTIVE OF SPONTANEOUS HCV RNA CLEARANCE IN PATIENTS WITH THALASSEMIA MAJOR. Journal of Hepatology, 2010, 52, S452.	1.8	4
300	Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 1003-1010.	0.4	4
301	Optimization of direct antiâ€viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterology Journal, 2018, 6, 225-237.	1.6	4
302	A New Intraepithelial γδT-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Digestive Diseases and Sciences, 2020, 66, 3352-3358.	1.1	4
303	Multiple intrahepatic vascular shunts causing hyperammoniaemic encephalopathy in a patient without liver cirrhosis. Digestive and Liver Disease, 2006, 38, 347-351.	0.4	3
304	Screening and treatment of portal vein thrombosis in cirrhosis. Digestive and Liver Disease, 2017, 49, 228-229.	0.4	3
305	Endoscopic stenting for colorectal cancer obstruction as a bridgeâ€toâ€surgery strategy. European Journal of Clinical Investigation, 2020, 50, e13252.	1.7	3
306	Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study. International Journal of Colorectal Disease, 2021, 36, 1561-1568.	1.0	3

#	Article	IF	Citations
307	New biologics in the management of Crohn's disease: focus on certolizumab pegol. Clinical and Experimental Gastroenterology, 2009, 2, 61-8.	1.0	3
308	Somatostatin (SS) and Gabexate (GM) Are Ineffective in Preventing Post-ERCP Complications. Gastrointestinal Endoscopy, 2004, 59, P106.	0.5	2
309	Reply to Dr. Barkun's Letter. American Journal of Gastroenterology, 2005, 100, 2133-2134.	0.2	2
310	Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection. Alimentary Pharmacology and Therapeutics, 2006, 23, 1329-1335.	1.9	2
311	Affinity analysis of differentially expressed genes in hepatocytes expressing HCV core genotype 1b or 3a. BioSystems, 2013, 114, 64-68.	0.9	2
312	Tu1388 DEVELOPMENT AND VALIDATION OF A RISK STRATIFICATION SCORE FOR POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) PANCREATITIS. Gastrointestinal Endoscopy, 2018, 87, AB573.	0.5	2
313	Inverted colonic diverticulum (ICD): report of two cases and literature review of a not that unusual endoscopic challenge. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101711.	0.7	2
314	URINARY IMMUNOREACTIVE TRYPSIN IN PANCREATIC CANCER. Lancet, The, 1980, 315, 93.	6.3	1
315	Serum trypsinogen. Digestive Diseases and Sciences, 1984, 29, 479-479.	1.1	1
316	Benign duodenocolic fistula: an unusual case of gastrointestinal bleeding. Gastrointestinal Endoscopy, 1993, 39, 827-830.	0.5	1
317	Randomized study on two "rescue―therapies for H. pylori infected patients after failure of standard "triple therapy―regimens. Gastroenterology, 2000, 118, A881.	0.6	1
318	Efficacy Versus Effectiveness of Octreotide in the Prophylaxis of Post-ERCP Pancreatitis. American Journal of Gastroenterology, 2007, 102, 1539-1539.	0.2	1
319	Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV. New England Journal of Medicine, 2007, 357, 1660-1662.	13.9	1
320	High dose of octreotide as a prophylaxis of post-ERCP pancreatitis. Gastrointestinal Endoscopy, 2007, 66, 421.	0.5	1
321	Are HCV genotypes 2 and 3 the same or different?. Current Hepatitis Reports, 2008, 7, 88-92.	0.3	1
322	Reply:. Hepatology, 2008, 48, 1020-1021.	3.6	1
323	Response to Garcia-Cano. American Journal of Gastroenterology, 2008, 103, 489-490.	0.2	1
324	Response to Lin. American Journal of Gastroenterology, 2009, 104, 1595-1596.	0.2	1

#	Article	IF	Citations
325	Optimal dosage of ribavirin. Hepatology, 2010, 52, 1173-1174.	3.6	1
326	How evidence-based are current guidelines for managing patients with peptic ulcer bleeding?. World Journal of Gastrointestinal Surgery, 2010, 2, 9.	0.8	1
327	The specialty of gastroenterology: Between a past of excellence and a somewhat uncertain future. Digestive and Liver Disease, 2010, 42, 606-607.	0.4	1
328	Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2011, 17, 1834-1835.	0.9	1
329	Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia. Digestive and Liver Disease, 2014, 46, 621-624.	0.4	1
330	Support Vector Machine Based on microRNA Expression Profiles to Predict Histological Origin of Ampullary Carcinoma. Pancreas, 2016, 45, 626-629.	0.5	1
331	Transabdominal ultrasound-guided pancreatic biopsy: a neglected but safe, effective and inexpensive procedure that needs to be re-juvinalized. Journal of Ultrasound, 2021, 24, 175-182.	0.7	1
332	Circulating levels of cytokines, chemokines and growth factors in patients with achalasia. Biomedical Reports, 2021, 15, 92.	0.9	1
333	Survival of Patients with Early Gastric Cancer Operated on for Cure., 1990,, 19-25.		1
334	The IdNUD-lookd study: An italian multicenter observational study of non ulcer dyspepsia: Does helicobacter pylori eradication improve symptoms?. Gastroenterology, 2000, 118, A1292.	0.6	0
335	A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis. Journal of Hepatology, 2002, 36, 117.	1.8	0
336	Mutations in cystic fibrosis transmembrane conductance regulator (CFTR), cationic trypsinogen (PRSS1), and pancreatic secretory inhibitor (PSTI/SPINK1) genes in alcoholics with either chronic pancreatitis or liver disease. Gastroenterology, 2003, 124, A582.	0.6	0
337	Administration of autologous erythrocytes loaded with dexamethasone 21-phosphate is effective in steroid-dependent IBD. Gastroenterology, 2003, 124, A519.	0.6	0
338	Need for colectomy in Ulcerative Colitis (UC). Gastroenterology, 2003, 124, A209.	0.6	0
339	Response:. Gastrointestinal Endoscopy, 2007, 65, 359.	0.5	0
340	Response:. Gastrointestinal Endoscopy, 2008, 67, 190-191.	0.5	0
341	0542: Use of Contrast Enhanced Ultrasonography (CEUS) in the Assessment of Focal Liver Lesions in Pediatric Patients. Ultrasound in Medicine and Biology, 2009, 35, S78-S79.	0.7	0
342	Endoscopic Dual Versus Monotherapy in Patients Bleeding from High-Risk Peptic Ulcers. Gastrointestinal Endoscopy, 2009, 69, AB205.	0.5	0

#	Article	IF	CITATIONS
343	S1540: Laterally Spreading Tumors (LST) of the Colon: What Is the Role of Endoscopic Mucosal Resection (EMR) in the Endoscopic Submucosal Dissection (ESD) Era?. Gastrointestinal Endoscopy, 2010, 71, AB189.	0.5	0
344	Dissection of the Crohn's Disease Transcriptome of 71 Loci Using Genome-Wide Microarrays. Gastroenterology, 2011, 140, S-272-S-273.	0.6	0
345	MicroRNA and Colon-Cancer: The Circadian Clock Connection. Gastroenterology, 2011, 140, S-820.	0.6	0
346	Transperineal ultrasound (TPUS) in pediatric perianal disease. Digestive and Liver Disease, 2014, 46, e78.	0.4	0
347	HCV genotype 1a and 1b: Similarities and differences in clinical features, therapeutic outcome and predictors of response. Digestive and Liver Disease, 2014, 46, e44.	0.4	0
348	Reply to "Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools― Journal of Hepatology, 2014, 61, 179-180.	1.8	0
349	Letter: <scp>HB</scp> sAg kineticsâ€guided interferon therapy for chronic hepatitis D – authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 481-482.	1.9	0
350	Addendum: Palmieri, O. et al. Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. Int. J. Mol. Sci. 2017, 18, 1580. International Journal of Molecular Sciences, 2017, 18, 2113.	1.8	0
351	Guidelines for treatment of acute pancreatitis. Gut, 1999, 44, 579-579.	6.1	О